Health-related quality of life overlooked in cancer drug studies

October 1, 2018, McMaster University
Feng Xie, senior author and a professor of the Department of Health Research Methods, Evidence, and Impact at McMaster. Credit: McMaster University

A McMaster University-led review and analysis of randomized clinical trials is questioning whether interventions which prolong progression-free survival in cancer patients, improve their health-related quality of life.

The systematic review and quantitative analysis of 52 articles reporting on 38 randomized clinical trials involving 13,979 across 12 cancer types revealed no significant association between survival when the disease is not getting worse, or "progression-free survival", and health-related of .

The results were published today in the Journal of the American Medical Association (JAMA) Internal Medicine.

"Given the increased use of progression-free survival as the primary outcome in new oncology trials, and uncertainty of overall survival, it remains possible that patients are receiving toxic and/or expensive treatments without experiencing important benefit," said Feng Xie, senior author of the study and a professor of the Department of Health Research Methods, Evidence, and Impact at McMaster.

The research team conducted the review of human cancer published from January 2000 to May 2016, screening 35,960 records. To increase comprehensiveness of the study, the researchers included a list of drugs approved by the U.S. Food and Drug Administration (FDA) based on progression-free survival benefit, and set no language limitations.

Originally developed as a measurement tool to identify activity in the early development of drugs, progression-free survival has become a widely-used surrogate outcome in . The increasing use of this measurement is also reflected in drug regulatory approvals, with at least a dozen drugs approved by the FDA between 2005 and 2010 using progression-free survival as a primary end point.

"There are only two reasons to use progression-free survival as a valid end point in oncology," said Xie. "One is that it is a valid surrogate marker for overall survival. The second is the assumption that patients who live longer without disease progression will have better health-related quality of life, even without longer survival."

The results suggest future studies include rigorous and trustworthy measurement of health-related quality of life in cancer trials.

"Access to these types of drugs is costing our healthcare system a lot of money, and the troubling fact is that we do not have strong enough evidence to show that some of these drugs can extend a patient's life or improve their quality of life," Xie said.

"Therefore, to ensure patients are truly obtaining important benefit from therapies, clinical trial investigators should measure health-related quality of life directly and accurately, ensuring adequate duration and follow-up, and publish it."

Within the scientific research community, Xie argued for the need to "revisit this issue of using surrogate outcomes to measure the safety and efficacy of new oncology drugs."

Explore further: Cetuximab+RT found to be inferior to standard treatment in HPV+ oropharyngeal cancer

More information: Journal of the American Medical Association (2018). DOI: 10.1001/jamainternmed.2018.4710

Related Stories

Cetuximab+RT found to be inferior to standard treatment in HPV+ oropharyngeal cancer

August 14, 2018
An interim analysis of data from a randomized clinical trial of patients with human papillomavirus (HPV)-positive oropharyngeal cancer found that treatment with radiation therapy and cetuximab is associated with worse overall ...

Metastatic breast cancer: Bevacizumab slows progression, but has no impact on survival

July 10, 2012
The cancer drug bevacizumab (Avastin) offers only a modest benefit in delaying disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers. The researchers assessed ...

Cabozantinib improves survival in advanced hepatocellular cancer

July 8, 2018
(HealthDay)—Cabozantinib results in significantly longer overall and progression-free survival than placebo among patients with advanced hepatocellular carcinoma, according to a study published in the July 5 issue of the ...

Can cancer vaccines prolong survival?

April 6, 2015
Therapeutic anti-cancer vaccines developed to treat metastatic disease such as advanced prostate cancer or melanoma rarely have a noticeable effect on the tumor but have been associated with a statistically significant increase ...

Gender difference in survival seen after radical cystectomy

June 20, 2018
(HealthDay)—Compared with males, females who undergo radical cystectomy for bladder cancer have worse disease-free, cancer-specific, and overall survival, according to a review published in the July issue of The Journal ...

Some cancer drugs approved in Europe might not have sufficient evidence of survival benefits, says study

October 6, 2017
Most cancer drugs approved in Europe from 2009-2013 weren't backed by sufficient scientific evidence that they work, according to a new study.

Recommended for you

Survivors of childhood Hodgkin lymphoma face high long-term risk of solid cancers

December 17, 2018
New research refines existing evidence that survivors of childhood Hodgkin lymphoma face an elevated risk of developing various types of solid tumors many years later. In addition, certain subgroups of patients have an especially ...

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.